The results showed that LSM2 expression was significantly increased in 10 tumors, including diffuse large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), ovarian cancer (OV), pancreatic adenocarcinoma (PAAD), SKCM, testicular germ cell tumors (TGCT), and thymoma (THYM). Here, LSM2 is linked to ovarian carcinoma.